Skip to main content

Table 4 Commonly recommended adjuvant chemotherapy regimens

From: Progress in adjuvant chemotherapy for breast cancer: an overview

Recurrence risk category and definition Recommended regimens: ER-positive, HER2-negative Recommended regimens: ER/PR-negative, HER2-negative Recommended regimens: HER2-positive
Very low risk
• Node-Neg, T1a No chemotherapy No chemotherapy No chemotherapy
Low risk
• Node-Neg, T1b Consider second generation chemotherapy regimen if RS is high Consider second generation chemotherapy regimen Consider weekly paclitaxel + H
• Node-Neg, T1c, Second generation chemotherapy regimen if RS is high (or consider if intermediate) Second generation chemotherapy regimen Weekly paclitaxel + H or TCH
Moderate risk
• Node-Neg, T2 Second or third generation chemotherapy regimen if RS intermediate-high Third generation chemotherapy regimen AC-T + H or TCH +/− P
High risk
• 1+ Pos Nodes or T3 Third generation chemotherapy regimen if RS intermediate-high (or 4+ positive nodes irrespective of RS) Third generation chemotherapy regimen AC-T + H or TCH+/−P
  1. TCH, Docetaxel, carboplatin, trastuzumab; T, Paclitaxel; AC, Doxorubicin, cyclophosphamide; H, Trastuzumab; P, Pertuzumab; Neg, Negative; Pos, Positive; RS, Recurrence score.